NEWS

By: Dan Leonard, Executive Director, We Work For Health Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives. Last year marked a transformative moment for the biopharmaceutical sector: the industry committed to nearly $500 billion in domestic investments, an almost 1,500% surge compared to 2024. My organization, We Work For Health, documents where these investments flow on our U.S. Biopharma Investment Wa

By: Richard Bagger, Board Member, Center for Medicine in the Public Interest; former New Jersey State Legislator and Chief of Staff to New Jersey Governor Chris Christie.  When government officials propose policies that set prices for life-saving medicines, the idea can sound simple: make prescription drugs more affordable and easier to access. But history, economics, and global experience tell a much different story. Government price controls, including importing other count

By: Debbie Hart, CEO, BioNJ and Dan Leonard, Executive Director, We Work For Health Will the epicenter of global medical innovation be in New Jersey or Shanghai? That is a critical question before U.S. policymakers right now, and the stakes arguably couldn’t be higher. How the country fends off China’s rising biopharma sector affects everything from our health and national security to local, state and national economies. Today, the U.S. leads the world in biopharmaceutical in

By: Dan Leonard, Executive Director, We Work For Health The decades-long partnership between the federal government, research-focused...

By: Dan Leonard, Executive Director, We Work For Health Kansas is both a driver and a beneficiary of the most sustained period of growth...

By: Tom Kowalski, Co-Chair, We Work For Health Recent efforts to revive the so-called “Most Favored Nation” (MFN) drug pricing policy...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health What do North Carolina’s incredible universities have in common, in...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health Smart policymaking and American ingenuity have combined to create an...

While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...

The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...

Forty-three years ago, a young U.S. Sen. Joe Biden voted for a transformative policy reform that subsequently catalyzed upwards of $2...